Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" and the rating has been maintained [1] Core Views - The report emphasizes three core investment directions: 1) Breakthroughs in cutting-edge technologies (e.g., First-in-class drugs in oncology, weight loss, autoimmune fields, and innovative devices like brain-machine interfaces); 2) Clinical validation and commercialization potential (focus on the progress of domestic innovative drugs going abroad and the clinical development progress post-BD transactions); 3) Efficiency advantages in the industry chain (CXO leaders and high-value consumables' global layout) [8] Industry Review - The pharmaceutical and biotechnology industry index increased by 0.81%, ranking 21st among 31 primary industries, outperforming the CSI 300 index which decreased by 0.27% [5][16] - The sub-industries of pharmaceutical circulation and in vitro diagnostics saw significant gains of 7.61% and 5.32% respectively, while medical research outsourcing and medical devices experienced declines of 3.49% and 1.76% [5][16] - As of November 14, 2025, the industry PE (TTM overall method, excluding negative values) was 30.89x, up from 30.67x in the previous period, indicating an upward valuation trend that remains below the average [21] - The top three PE ratios among the sub-industries were for vaccines (50.42x), hospitals (43.67x), and medical devices (37.84x), while pharmaceutical circulation had the lowest valuation at 15.46x [21] Important Industry News - The National Health Commission and others issued implementation opinions to promote and regulate the application of "AI + healthcare" [7] - The NMPA released a new version of the "Medical Device Production Quality Management Specifications" [7] - Novartis received NMPA approval for its first radioligand therapy drug "Pluvicto®" for dual indications [7] - Sanofi's innovative targeted nano-antibody "Cablivi®" was approved by NMPA for treating immune-mediated thrombotic thrombocytopenic purpura [7] - The U.S. government reached a drug price control agreement with Eli Lilly and Novo Nordisk, leading to significant price reductions for GLP-1 drugs [7]

证券代码：301230 证券简称：泓博医药 公告编号：2025-064 上海泓博智源医药股份有限公司 2025 年第三次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： 1、本次股东会不存在新增、修改、否决议案的情形； 2、本次股东会不存在变更前次股东会决议的情形； 3、本次股东会采取现场投票与网络投票相结合的方式进行。 一、会议召开情况 1、会议通知方式：公告方式 2、会议召开时间： （1）现场会议召开时间：2025 年 11 月 14 日（星期五）14:00 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的时间为 2025 年 11 月 14 日上午 9:15~9:25，9:30~11:30 和下午 13:00~15:00；通过深圳证券交易所互联网 投票系统投票的具体时间为 2025 年 11 月 14 日 9:15～15:00 任意时间。 3、现场会议地点：上海浦东新区凯庆路 59 号 12 幢公司一楼会议室 4、会议召开方式：本次股东会采取现场投票、网络投票相结合的方式。 6、现场会议主持人：公司董事长 Pin ...

致：上海泓博智源医药股份有限公司 北京市嘉源律师事务所 关于上海泓博智源医药股份有限公司 2025 年第三次临时股东会的 北京市嘉源律师事务所 关于上海泓博智源医药股份有限公司 2025 年第三次临时股东会的 法律意见书 西城区复兴门内大街 158 号远洋大厦 4 楼 中国·北京 北京 BEIJING·上海 SHANGHAI·深圳 SHENZHEN·香港 HONG KONG·广州 GUANGZHOU·西安 XI'AN 法律意见书 嘉源(2025)-04-823 北京市嘉源律师事务所（以下简称"本所"）接受上海泓博智源医药股份有 限公司（以下简称"公司"）的委托，根据《中华人民共和国公司法》（以下简称 "《公司法》"）《上市公司股东会规则》（以下简称"《股东会规则》"）等现行有效 的法律、行政法规、部门规章、规范性文件（以下简称"法律法规"）以及《上 海泓博智源医药股份有限公司章程》（以下简称"《公司章程》"）的有关规定，指 派本所律师对公司 2025 年第三次临时股东会（以下简称"本次股东会"）进行见 证，并依法出具本法律意见书。 为出具本法律意见书，本所指派律师现场见证了本次股东会，查阅了公司提 供的与本次 ...

Group 1 - The core point of the article is that Hongbo Pharmaceutical announced a cash dividend distribution plan for the first half of 2025, proposing a payout of 0.7 RMB per 10 shares to all shareholders [1] - The record date for the dividend distribution is set for November 13, 2025, and the ex-dividend date is November 14, 2025 [1]

证券代码：301230 证券简称：泓博医药 公告编号：2025-063 上海泓博智源医药股份有限公司 2025年半年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 总股本 139,586,605 股扣除回购专用账户中已回购股份后 137,540,405 股为基数测算，共 计派发现金股利约 9,627,828.35 元（含税）。若在本利润分配方案实施前公司总股本发 生变动，公司将按照分配比例不变的原则对分配总额进行调整。 2、自分配方案披露至实施期间，本公司股本总额未发生变化。因公司实施回购方 案，公司回购专用账户持有的 2,046,200 股不参与本次利润分配。 1、上海泓博智源医药股份有限公司（以下简称"公司"或"本公司"）回购专用 证券账户中的股份 2,046,200 股不参与本次权益分派。公司 2025 年半年度权益分派方案 为：以公司现有总股本 139,586,605 股扣除回购专用账户中已回购股份 2,046,200 股后的 137,540,405 股为基数，向全体股东每 10 股派发现金红利 0.7 元（含税），送红 ...

Group 1 - The CRO index experienced fluctuations and a downward trend on November 4th [1] - Among the constituent stocks, Shengnuo Bio, Hongbo Pharmaceutical, and Chengdu XianDao had the largest declines, with decreases of 3.80%, 3.79%, and 3.53% respectively [1]

Core Viewpoint - On November 3, a total of 12 listed companies will have their restricted shares unlocked, with a total market value of approximately 8.307 billion yuan [1] Summary by Category Restricted Share Unlocking Details - Yunding Technology (Stock Code: 000409) will unlock 153 million shares from a private placement of A-shares [1] - China Unicom (Stock Code: 600050) will unlock 250 million shares related to equity incentive restrictions [1] - Ningbo Yunsheng (Stock Code: 600366) will unlock 5.857 million shares from equity incentives [1] - Changrun Co., Ltd. (Stock Code: 603201) will unlock 387,500 shares from equity incentives [1] - Lingda Co., Ltd. (Stock Code: 300125) will unlock 630,000 shares from equity incentives [1] - Wanda Information (Stock Code: 300168) will unlock 1.2701 million shares from equity incentives [1] - Qunxing Toys (Stock Code: 002575) will unlock 7.2 million shares from equity incentives [1] - Lushan New Materials (Stock Code: 603051) will unlock 391,200 shares from equity incentives [1] - Hongbo Pharmaceutical (Stock Code: 301230) will unlock 4.8251 million shares from pre-issue restrictions [1] - Oppein Home (Stock Code: 603551) will unlock 60,000 shares from equity incentives [1] - Yihe Jiaye (Stock Code: 301367) will unlock 2.34362 million shares from pre-issue restrictions [1] - Ruina Intelligent (Stock Code: 301129) will extend the lock-up period for 8.8992 million shares [1]

Core Viewpoint - On November 3, a total of 7 companies had their restricted shares unlocked, with a total unlock volume of 242 million shares, amounting to a market value of 4.354 billion yuan based on the latest closing prices [1] Summary by Category Unlock Volume - The companies with the highest unlock volumes are Yunding Technology, Hongbo Pharmaceutical, and Ruina Intelligent, with unlock shares of 153 million, 48.755 million, and 28.917 million shares respectively [1] Unlock Market Value - In terms of unlock market value, Yunding Technology, Hongbo Pharmaceutical, and Ruina Intelligent lead with market values of 1.74 billion yuan, 1.686 billion yuan, and 748 million yuan respectively [1] Unlock Ratio - The companies with the highest unlock ratios relative to their total share capital are Hongbo Pharmaceutical, Yunding Technology, and Ruina Intelligent, with unlock ratios of 34.93%, 22.61%, and 21.28% respectively [1]

Group 1 - A total of 7 companies had their restricted shares unlocked on November 3, with a combined unlock volume of 242 million shares, valued at 4.354 billion yuan based on the latest closing prices [1] - The companies with the highest unlock volumes are Yunding Technology, Hongbo Pharmaceutical, and Ruina Intelligent, with unlock shares of 153 million, 48.76 million, and 28.92 million respectively [1] - In terms of unlock value, Yunding Technology, Hongbo Pharmaceutical, and Ruina Intelligent lead with unlock values of 1.74 billion yuan, 1.686 billion yuan, and 748 million yuan respectively [1] - The highest percentage of total share capital unlocked is seen in Hongbo Pharmaceutical, Yunding Technology, and Ruina Intelligent, with unlock ratios of 34.93%, 22.61%, and 21.28% respectively [1]

Core Viewpoint - Hongbo Pharmaceutical (301230.SZ) has signed a supplementary agreement to extend the action agreement among its actual controllers until October 31, 2025, reflecting confidence in the company's long-term development and aiming to enhance operational decision-making efficiency [1] Group 1 - The supplementary agreement to the action agreement among Ping Chen, An Rongchang, and Jiang Shengli will expire on October 31, 2025 [1] - The voting rights entrustment relationship between shareholders of Pharma Resources Holding Co., Ltd. and Ping Chen will also expire on October 31, 2025 [1] - The parties involved have signed a new supplementary agreement to extend the action relationship, ensuring the company's stable development [1] Group 2 - Hongjian Zhang and Michael Gao have recently signed revised voting rights entrustment agreements with Ping Chen to extend their voting rights relationship [1] - The voting rights entrustment relationship between Genesis and Ping Chen will not be renewed [1]